维普期刊资源整合服务平台（V6.5）

28篇 您的检索式：作者名="Keith F T"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Dynamic model- ing of a dual clearance squeeze film damper:Part I test rigand dynamic model with one damper显示文摘	Moraru L Keith T G Jr Dimofte F	2003	Tribology Trans- actions2003，46，2：	1
2	Dynamic model- ing of a dual clearance squeeze film damper: Part II 显示文摘	Moraru L Keith T G Jr Dimofte F	2006	Tribology Transactions2006，49，4：	1
3	Characterization of polyploid wheat genomic diversity using a high-density 90 000 single nucleotide polymorphism array 显示文摘	Wang SC Debbie W Kerrie F Alexandra A Shiaoman C Bevan EH Marco M Silvio S Sara GM Luigi C Anna MM Alex W Stuart S Gary B Ralf W Joerg P International Wheat Genome Sequencing Consortium Morten L Diane M Rudi A Rudy D Gina BG Abraham K Alina RA Catherine F Jerome S Michele M Curtis P Luo MC Jan DMM Jorge D Martin G Roberto T Cindy L Ivan M Colin C Keith JE Matthew H Eduard A	2014	Plant Biotechnol J2014，12，：	1
4	A stability analysis for a hydrodynamic three-wave journal bearing显示文摘	Ene N M Dimofte F Keith J T G	2008	Tribology International2008，41，5：	1
5	Calculation of magnetic response properties using a continuous set of gauge trancformations显示文摘	Bader R F W	1993	Chem Phys Lett1993，210，123：	1
6	Calculation of magnetic response properties using atoms in molecules显示文摘	Bader R F W	1992	194(11992，3，：	1
7	Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations显示文摘	James W James F Keith T	2005	Clin Ther2005，27，11：	1
8	A white bentonite form San Juan Province,Argentina-geology and potential industrial applications显示文摘	Cravero F Keith K S Murray H H Toth T	2000	Applied Clay Science2000，16，：	1
9	A stability analysis for a hydrodynamic three-wave journal bearing 显示文摘	Ene N M Dimofte F Keith Jr T G	2008	Tribology International2008，41，：	1
10	Journal o{ Inorganic Biochemistry 显示文摘	Wolfhardt F Loria M Alessandra C Chiara B Keith F T Wolf gang L Laura El C	2008	102 13292008，102，：	1
11	A dynamic analysis of hy- drodynamic wave journal bearings 显示文摘	ENE N M DIMOFFE F KEITH T G	2008	Tribology Transactions2008，51，1：	1
12	Computation of pressurized gas bearings using the CE/SE method显示文摘	CIOC S DIMOFTE F KEITH T	2003	STLE Tribology Transactions2003，46，1：	1
13	Complications of laser in keratomileusis for the eorreetion of myopia 显示文摘	STULTING R D CARR T D KEITH F R	1999	Ophthal mology1999，106，1：	1
14	Bupropion for major depressive disorder:Pharmacokinetic and formulation considerations显示文摘	James W James F Keith T	2005	Clin Ther2005，27，11：	1
15	Bupropion for major depressive disorder:Pharmaeokinetie and formulation considerations显示文摘	James W James F Keith T	2005	Clin Ther2005，27，11：	1
16	Morphological changes in polyesters and polyamides induced by blending with small concentrations of polymer diluents显示文摘	Keith H D Padden F J Russell T P	1989	Macromol1989，22，：	1
17	Complications of laser in keratomileusis for the correction of myopia显示文摘	Stulting R D Carr T D Keith F R	1999	Ophthalmology1999，106，1：	1
18	Dynamic modeling of a dual clearance squeeze film damper:Part Ⅰ test rig and dynamic model with one damper显示文摘	Moraru L Keith T G Jr Dimofte F	2003	Tribology Transactions2003，46，2：	1
19	Dynamic modeling of a dual clearance squeeze film damper:Part Ⅱ 显示文摘	Moraru L Keith T G Dimofte F	2006	Tribology Transactions2006，49，4：	1
20	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs.	Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch	2017	World Journal of Virology2017，6，4：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示